Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa‐2b

作者：Shanshan Suo, Rongfeng Fu, Albert Qin, Zonghong Shao, Jie Bai, Hu Zhou, Na Xu, Suning Chen, Xuelan Zuo, Xin Du, Minghui Duan, Li Wang, Pei Li, Xuhan Zhang, Sujiang Zhang, Daoxiang Wu, Jingjing Zhang, Zhijian Xiao, Lei Zhang, Jie Jin · 发表于：British Journal of Haematology · 年份：2024 · DOI：10.1111/bjh.19846 · 被引用次数：17 · 研究领域：Myeloproliferative Neoplasms: Diagnosis and Treatment、Eosinophilic Disorders and Syndromes、Renal Diseases and Glomerulopathies

Polycythaemia vera (PV), a common type of BCR/ABL-negative myeloproliferative neoplasm, is associated with an overproduction of red blood cells and a risk of developing thromboembolic (TE) events, post-PV myelofibrosis, and even acute leukaemia.1, 2 Phlebotomy-free, blood parameter control as measured by complete haematological response (CHR, i.e. haematocrit <45% without phlebotomy, a platelet count ≤400 × 109/L, and a white blood cell count <10 × 109/L) is an accepted efficacy end-point for PV treatment and is crucial in reducing the risk of TE.3, 4 Patients with PV usually carry at least one mutation in the Janus kinase 2 gene (JAK2), with the JAK2V617F mutation being the most commonly identified.2 JAK2V617F is not the sole driver mutation in PV as other mutations such as JAK2 exon 12 mutations can also function with coexisting mutations and epigenetic changes to contribute to the occurrence and progression of PV. However, it is a reliable marker associated with neoplastic cells that drive the disease in patients carrying it.2, 5, 6 Ropeginterferon alfa-2b (ropeg), a novel polyethylene glycol-conjugated interferon (IFN)-based therapy that can be dosed once every 2–4 weeks, has demonstrated clinical efficacy and tolerability in multiple studies.7-10 It is approved for the treatment of PV in many countries and regions at an initiating dose of 100 μg (50 μg if receiving hydroxyurea [HU]) with 50 μg dose titrations every 2 weeks to a maximum dose of 500 μg. In addition, ropeg ...